Huntington's Disease Market Report 2025

The huntington's disease market size has grown rapidly in recent years. It will grow from $0.47 billion in 2024 to $0.55 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth during the historic period can be attributed to factors such as heightened awareness of chronic diseases, growing government awareness programs, increased government initiatives to promote awareness of Huntington's disease, a rising geriatric population, and increased research into genetic disorders.

The huntington's disease market size is expected to see rapid growth in the next few years. It will grow to $1.07 billion in 2029 at a compound annual growth rate (CAGR) of 17.8%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of neurological disorders, greater public awareness, rising healthcare spending, growing investments in research and development, and an expansion in clinical research activities. Key trends in the forecast period include the adoption of novel drugs, the development of numerous new drugs, the emergence of innovative technologies, advancements in technology, and a rising demand for advanced products.

The growing prevalence of neurological disorders is expected to drive the expansion of the Huntington's disease market in the future. Neurological disorders are conditions that affect the brain, spinal cord, and nerves, resulting in symptoms such as movement, coordination, sensory, or cognitive impairments. The rise in these disorders can be attributed to factors such as aging populations, exposure to environmental toxins, lifestyle changes, advancements in diagnostic techniques, and genetic factors that enable better detection and identification of cases. Huntington's disease, a neurodegenerative disorder caused by a genetic mutation, leads to motor dysfunction, cognitive decline, and psychiatric symptoms, all of which progressively worsen over time. For example, in March 2023, the Alzheimer’s Association, a U.S.-based nonprofit health organization, reported that an estimated 6.7 million Americans aged 65 and older are currently living with Alzheimer's dementia. Without breakthroughs to prevent, slow, or cure the disease, this number could increase to 13.8 million by 2060. This growing prevalence of neurological disorders is thus fueling the growth of the Huntington's disease market.

Companies in the Huntington's disease market are focusing on creating innovative treatments, including oral small molecule drugs, to alleviate symptoms and slow disease progression. These drugs are low-molecular-weight compounds that can be taken orally and are designed to interact with biological targets such as proteins or enzymes to treat diseases. For instance, in September 2024, PTC Therapeutics Inc., a U.S.-based pharmaceutical company, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its PTC518 program, which targets Huntington's disease. This designation is given to therapies addressing significant unmet medical needs, underlining the potential of PTC518 as a disease-modifying treatment for individuals with this genetic disorder.

In December 2024, PTC Therapeutics, Inc. entered into a partnership with Novartis AG to expedite the development of PTC518 as an oral treatment for Huntington's disease. Novartis AG, a pharmaceutical company based in Switzerland, specializes in providing treatments such as branaplam (LMI070) for Huntington's disease.

Major players in the huntington's disease market are Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Ipsen S.A., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics Inc., Annexon Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Vaccinex Inc., SOM Biotech S.L., Alterity Therapeutics Limited, and Medesis pharma SA.

North America was the largest region in the huntington's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in huntington's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the huntington's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Huntington's disease is a rare, inherited neurodegenerative condition that causes the gradual degeneration of nerve cells in the brain, resulting in uncontrolled movements, cognitive decline, and emotional disturbances. It is caused by a genetic mutation in the HTT gene and generally manifests in mid-adulthood.

The primary treatment options for Huntington's disease include symptomatic therapy, disease-modifying therapy, and other types of treatments. Symptomatic therapy aims to alleviate symptoms such as movement disorders, psychiatric issues, and cognitive decline, but does not slow the progression of the disease. Diagnosis is made through various methods, including magnetic resonance imaging (MRI), computed tomography (CT) scans, genetic testing, and other diagnostic tools. Medications are delivered through various routes, such as oral, parenteral, and other methods. These drugs are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, and are used by a range of end users, including hospitals, home care services, specialty clinics, and other healthcare providers.

The huntington’s disease market research report is one of a series of new reports that provides huntington’s disease market statistics, including the huntington’s disease industry global market size, regional shares, competitors with the huntington’s disease market share, detailed huntington’s disease market segments, market trends, and opportunities, and any further data you may need to thrive in the huntington’s disease industry. This huntington’s disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The huntington's disease market consists of revenues earned by entities by providing services such as medical management, psychological and social support, and physical, occupational, and speech therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The Huntington's disease market also includes sales of tetrabenazine, deutetrabenazine, and antidepressants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.